Vote Scores

Home / Companies / CRISPR THERAPEUTICS AG / 5 Jun 2025

Meeting · year to 30 June 2025516 filers reporting

CRISPR THERAPEUTICS AG: meeting of 5 Jun 2025

Votes reported on Form N-PX, item by item

516 Form N-PX filers reported votes at the CRISPR THERAPEUTICS AG meeting of 5 Jun 2025. Their records fall into 7 items below, in ballot order: management items first, then proposals from security holders. Each bar shows how the reporting filers split; it is not the result of the meeting.

foragainstabstain, withhold or otheramber tick: the portion cast against management

Items

1

DIRECTOR ELECTIONSIssuer

Director elections

15 nominees; 70.1% of reported votes for; 55 filers withheld from or voted against at least one nominee.

1,939 vote records from 75 filers. 9 of the 70 filers that marked the item either way voted against management. 5 filers reported this item without a management mark.

80.0% for13.3% against6.7% other12.9% against management75 filers
2

SECTION 14A SAY-ON-PAY VOTESIssuer

Advisory vote on executive pay (say-on-pay)

823 vote records from 508 filers. 284 of the 473 filers that marked the item either way voted against management. 35 filers reported this item without a management mark.

35.6% for56.1% against8.3% other60.0% against management508 filers76.8% for23.2% against0.0% other23.1% against management54,514,814 reported shares
3

AUDIT-RELATEDIssuer

Audit-related items (auditor ratification)

139 vote records from 74 filers. 2 of the 69 filers that marked the item either way voted against management. 5 filers reported this item without a management mark.

90.5% for1.4% against8.1% other2.9% against management74 filers99.9% for0.0% against0.1% other0.1% against management18,326,563 reported shares
4

CAPITAL STRUCTUREIssuer

CAPITAL STRUCTURE: management items

Management items in this category are shown together; filers word and number them differently.

118 vote records from 65 filers. 0 of the 60 filers that marked the item either way voted against management. 5 filers reported this item without a management mark.

92.3% for0.0% against7.7% other0.0% against management65 filers100.0% for0.0% against0.0% against management8,668,099 reported shares, counted once per item in this group
5

COMPENSATIONIssuer

COMPENSATION: management items

Management items in this category are shown together; filers word and number them differently.

831 vote records from 80 filers. 36 of the 75 filers that marked the item either way voted against management. 5 filers reported this item without a management mark.

38.8% for48.8% against12.5% other48.0% against management80 filers93.4% for6.6% against6.4% against management109,940,686 reported shares, counted once per item in this group
6

CORPORATE GOVERNANCEIssuer

CORPORATE GOVERNANCE: management items

Management items in this category are shown together; filers word and number them differently.

801 vote records from 73 filers. 0 of the 68 filers that marked the item either way voted against management. 5 filers reported this item without a management mark.

93.2% for0.0% against6.8% other0.0% against management73 filers88.5% for11.5% against11.4% against management83,087,402 reported shares, counted once per item in this group
7

OTHERIssuer

OTHER: management items

Management items in this category are shown together; filers word and number them differently.

57 vote records from 17 filers. 2 of the 16 filers that marked the item either way voted against management. 1 filer reported this item without a management mark.

47.1% for11.8% against41.2% other12.5% against management17 filers98.5% for1.4% against0.0% other1.5% against management19,963,899 reported shares, counted once per item in this group

How the largest families voted

Family1. Directors2. Say-on-pay3. Auditor
VanguardForAgainst *For
BlackRock and iSharesForAgainst *For
FidelityForAgainst *For
DimensionalForAgainst *For
State Street and SPDRForAgainst *For
American CenturyForAgainst *For
Franklin TempletonForAgainst *For
InvescoForAgainst *For
EquitableAgainst *Against *For
Charles SchwabForAgainst *For
ProShares and ProFundsForAgainst *For
John Hancock and ManulifeForAgainst *For
Morgan Stanley, Eaton Vance and CalvertNo reportAgainst *No report
J.P. MorganForAgainst *For
Goldman SachsForAgainst *For
WisdomTreeForAgainst *For
PGIM and PrudentialForAgainst *For
Jackson National fundsAgainst *Against *For
Northern Trust and FlexSharesForAgainst *For
SEINo reportAgainst *No report
T. Rowe PriceForAgainst *For
Lincoln FinancialAgainstAgainstFor
First TrustNo reportAgainst *No report
NationwideAgainst *Against *For
Brighthouse FundsForAgainst *For
Guggenheim and RydexForAgainst *For
Columbia ThreadneedleNo reportForNo report
BNY MellonNo reportAgainst *No report
Capital Group and American FundsForForFor
Global XForAgainst *For
AllianceBernsteinNo reportAgainst *No report
MassMutualForAgainst *For
Neuberger BermanNo reportAgainst *No report
American BeaconForForFor
Natixis and Loomis SaylesAgainst *Against *For
BairdNo reportAgainst *No report

* against management. A family's position is the way most of its reported shares were voted across its filers; "split" means no single position led. "No report" means none of the family's filers listed the item.

Questions

How did large funds vote at the CRISPR THERAPEUTICS AG meeting?

516 Form N-PX filers reported votes at the meeting of 5 Jun 2025. On say-on-pay, 284 of 473 voted against management (60.0%). The family table lists each of the largest families item by item.

Is this the meeting result?

No. These are the votes of funds and managers that file Form N-PX, counted by filer and by the shares they reported. The certified result, which includes every shareholder, is reported by CRISPR THERAPEUTICS AG on Form 8-K.

Why are director elections shown as counts only?

Director records name the nominee. This site does not publish pages or rows about individuals, so for director elections it keeps the number of nominees and the split of votes and discards the wording.

Every meeting on file for CRISPR THERAPEUTICS AG

Provenance: SEC EDGAR, Form N-PX and N-PX/A filings listing CRISPR THERAPEUTICS AG with a meeting date within three days of 5 Jun 2025. Proposal titles are the most common wording among filers and are replaced by the SEC category where a wording could name a person. Not verified by the SEC. Filings read through 23 Sep 2026.